BusinessAvid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius® 2,000-Liter Single-Use Bioreactors in Its Myford FacilityBy Nasdaq OMXSep 25, 2017, 12:05 PM UTC
BusinessAvid Bioservices to Exhibit at 2017 BioProcess International Conference & ExhibitionBy Nasdaq OMXSep 19, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid BioservicesBy Nasdaq OMXSep 11, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed GlioblastomaBy Nasdaq OMXSep 7, 2017, 12:10 PM UTC
BusinessPeregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017By Nasdaq OMXSep 6, 2017, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXSep 5, 2017, 8:05 PM UTC
BusinessAvid Bioservices to Exhibit at The Bioprocessing Summit 2017By Nasdaq OMXAug 16, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent DevelopmentsBy Nasdaq OMXJul 14, 2017, 8:13 PM UTC
